section name header

Indications

High Alert


Alymsys, Avastin, Avzivi, Mvasi, Vegzelma, and ZirabevAvastin, Mvasi, Vegzelma, and ZirabevAvastin only

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Availability

Route/Dosage

Colorectal Cancer

Lung Cancer or Cervical Cancer

Glioblastoma or Renal Cell Carcinoma

Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Following Surgical Resection

Hepatocellular Carcinoma

US Brand Names

Alymsys, Avastin, Avzivi, Mvasi, Vegzelma, Zirabev

Action

  • A monoclonal antibody that binds to vascular endothelial growth factor, preventing its attachment to binding sites on vascular endothelium, thereby inhibiting growth of new blood vessels (angiogenesis).
Therapeutic effects:
  • Decreased metastatic disease progression and microvascular growth.

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: monoclonal antibodies

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 20 days (range 11–50 days).

Canadian Brand Names

Abevmy, Aybintio, Bambevi

Time/Action Profile

ROUTEONSETPEAKDURATION
IVrapidend of infusion14 days



Patient/Family Teaching

Pronunciation

be-va-SIZ-uh-mab